Brian Hilberdink, President of Novo Nordisk Canada, highlights the key role that Canada plays as a pilot market for exporting best practices globally, the focus that Novo Nordisk is placing on the undertreated condition of obesity in Canada, and the challenges and opportunities of running an innovative pharma business in Canada.
Globally, Novo Nordisk has seen a few changes since 2016 with a new CEO and a bit of a geographic reorganization. What role does the Canadian affiliate play within global strategy?
"Fortunately, approximately half of the Canadian population is able to access drugs through private insurance, which allows for speedy coverage for most drugs used to treat chronic diseases like diabetes."
